Gaithersburg-based biotechnology firm GlycoMimetics “has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for the proposed initial public offering of shares of its common stock,” according to a press release.
GlycoMimetics is focused on the “discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role.”
Join our growing Slack community
Join 5,000 tech professionals and entrepreneurs in our community Slack today!
Donate to the Journalism Fund
Your support powers our independent journalism. Unlike most business-media outlets, we don’t have a paywall. Instead, we count on your personal and organizational contributions.
